Lantheus Holdings, Inc. (NASDAQ:LNTH) Position Lifted by Farallon Capital Management LLC

Farallon Capital Management LLC raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 53.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 2,279,227 shares of the medical equipment provider’s stock after purchasing an additional 796,000 shares during the period. Farallon Capital Management LLC owned 3.29% of Lantheus worth $182,999,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC increased its holdings in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. Principal Securities Inc. bought a new position in Lantheus during the fourth quarter worth $28,000. Fidelis Capital Partners LLC acquired a new position in Lantheus in the first quarter worth $34,000. Finally, Nkcfo LLC bought a new stake in Lantheus during the second quarter valued at $47,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Up 1.2 %

Shares of LNTH stock opened at $111.36 on Tuesday. The stock has a 50-day simple moving average of $105.27 and a 200 day simple moving average of $84.74. The stock has a market capitalization of $7.72 billion, a P/E ratio of 17.00 and a beta of 0.50. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter last year, the company posted $1.40 EPS. Lantheus’s revenue was up 22.5% on a year-over-year basis. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LNTH shares. JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. B. Riley raised their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Leerink Partners lifted their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Finally, Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $126.00.

Insiders Place Their Bets

In other news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at approximately $1,138,389.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Gary J. Pruden sold 12,530 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares in the company, valued at approximately $1,138,389.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock valued at $3,922,001 in the last three months. Insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.